IMI2 Launch to Further Innovative Medicines Initiative Success: Right Prevention and Treatment at the Right Time

2013 07 10 Written by Vaccines Europe

Vaccines Europe is pleased to announce the European Commission launch of the IMI2 public private partnership (PPP) in life science research, which will build upon the success of the Innovative Medicines Initiative (IMI) in a continued effort to bring innovative prevention and treatment options to patients. IMI is a public-private partnership between the European Commission and EFPIA, the European Federation of Pharmaceutical Industries and Associations and is currently Europe’s largest initiative to speed up the development of better and safer medicines.

Within the framework of the future EU Research programme Horizon 2020, IMI2 will aim to advance life science R&D in key areas of unmet medical needs including research across key cross-cutting and horizontal domains considered essential to enable the delivery of new generation safe and efficacious vaccines where conventional technologies have failed.

The EU is facing increasing challenges from ageing, emerging health threats such as healthcare-associated infections and antimicrobial resistance, high chronic disease incidence, low levels of prevention awareness, as well as suboptimal uptake of existing cost-effective vaccines across different stages of life. With these changes comes the need to extend the vision of vaccination from early life and childhood alone to the whole life span and from prevention to prevention and treatment. The resulting R&D on vaccines needs to address the changing risks and immunological characteristics of this life span.

This requires innovative solutions to understand and measure the immune system maturation, and tackle emerging/unmet medical needs. Research is also needed to better understand drivers underpinning inconsistent utilisation of available immunisation measures as hesitant behaviours increase and undermine individual and societal public health and exacerbate challenges to maintain healthcare systems financially sustainable.

Such challenges can only be tackled through a participatory and collaborative model of innovation where the expertise of centres of excellence in immunology, genetics, bioinformatics and other fundamental disciplines making up the meta-discipline of vaccinology – which are largely hosted by the public sector – can be combined to the know-how of the research-based vaccine companies operating in Europe.

“The ongoing IMI cycle is already contributing to tremendous advancements through key vaccine projects focusing on optimising data polling and the setting up of an efficient and sustainable infrastructure for rapid and integrated post-licensure monitoring of vaccines”, said the Vaccines Europe President, Andrea Rappagliosi. He added that “IMI2 will expand the objective of improving innovation to also cover how to improve patients’ access to innovation by supporting collaborative projects and building networks of industrial and academic experts, SMEs, researchers, patients, regulatory authorities and payers”.


More information on IMI2 is available here.

The IMI2 Strategic Research Agenda can be found here.


About Vaccines Europe: 

Vaccines Europe, formerly European Vaccine Manufacturers (EVM), is the specialised vaccines group within the European Federation of Pharmaceutical Industries and Associations (EFPIA), the professional association of the pharmaceutical industry in Europe. Formed in 1991, Vaccines Europe represents major innovative research-based global vaccine companies operating in Europe. Companies represented within Vaccines Europe are involved in research and development (R&D), clinical trials, production and marketing of vaccines and are dedicated to improving public health through immunisation. The Vaccines Europe members are: Abbott Biologicals, Crucell, GlaxoSmithKline Vaccines, MedImmune, MSD, Novartis Vaccines, Pfizer Vaccines, Sanofi Pasteur, Sanofi Pasteur MSD, and Takeda.